Needham Downgrades Verrica Pharmaceuticals (VRCA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Brookline Capital Markets Downgrades Verrica Pharmaceuticals (VRCA) to Hold
October 2, 2024 10:30 AM EDTBrookline Capital Markets analyst Kemp Dolliver downgraded Verrica Pharmaceuticals (NASDAQ: VRCA) from Buy to Hold.
For an analyst ratings summary and ratings history on Verrica Pharmaceuticals click here. For more ratings news on Verrica Pharmaceuticals click here.
Shares of Verrica Pharmaceuticals closed at $1.37 yesterday.
... MoreVerrica Pharmaceuticals (VRCA) Announces Restructuring of Commercial Organization
October 2, 2024 7:32 AM EDTVerrica Pharmaceuticals Inc. (Verrica or the Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH® for the treatment of molluscum... More
